Oxford Immunotec prices IPO below the range at $12, raising $64 million

Comment

Shutterstock photo

Oxford Immunotec Global, which sells diagnostic tests for latent tuberculosis infection (LTBI), raised $64 million by offering 5.4 million shares (all primary) at $12, below the range of $13 to $15. Oxford, which initially filed confidentially on 9/10/2013, plans to list on the NASDAQ under the symbol "OXFD". J.P. Morgan and Piper Jaffray acted as the lead managers on the deal.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.



This article appears in: News Headlines , IPOs


More from Renaissance Capital

Subscribe






Renaissance Capital
Contributor:

Renaissance Capital

IPOs
Follow on:

Find a Credit Card

Select a credit card product by:
Select an offer:
Search
Data Provided by BankRate.com